

## TALKMED GROUP LIMITED (Company Registration No. 201324565Z)

FINANCIAL STATEMENT ANNOUNCEMENT FOR THE SECOND QUARTER AND HALF YEAR ENDED 30 JUNE 2014.

## PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2 & Q3), HALF YEAR AND FULL YEAR RESULTS

- 1(a) An income statement and statement of comprehensive income, or a statement of comprehensive income for the group, together with a comparative statement for the corresponding period of the immediately preceding financial year.
- **1(a)(i)** The Directors of TalkMed Group Limited (the "Company") are pleased to announce the unaudited consolidated results of the Company and its subsidiary (collectively, the "Group") for the second quarter and half year ended 30 June 2014 ("Q2 2014" and "YTD 2014" respectively).

	Q2 2014 \$'000 (Unaudited)	Q2 2013 \$'000 (Unaudited)	Increase / (Decrease) %	YTD 2014 \$'000 (Unaudited)	YTD 2013 \$'000 (Unaudited)	Increase / (Decrease) %
Revenue	15,789	14,320	10.3%	30,233	27,039	11.8%
Other items of income						
Other income	-	-	-	61	4	1425.0%
Items of expense						
Employee benefits	(3,297)	(2,582)	27.7%	(6,537)	(5,273)	24.0%
Operating lease expenses	(182)	(71)	156.3%	(365)	(143)	155.2%
Other operating expenses	(602)	(1,780)	-66.2%	(715)	(2,701)	-73.5%
Profit before tax	11,708	9,887	18.4%	22,677	18,926	19.8%
Income tax expense	(2,079)	(1,520)	36.8%	(3,881)	(3,203)	21.2%
Profit for the year representing total comprehensive income for the year attributable to owners of the company	9,629	8,367	15.1%	18,796	15,723	19.5%

### 1(a)(ii) The net profit attributable to owners of the Company includes the following charges / (credits):

	Group					
	Q2 2014 \$'000 (Unaudited)	Q2 2013 \$'000 (Unaudited)	Increase / (Decrease) %	YTD 2014 \$'000 (Unaudited)	YTD 2013 \$'000 (Unaudited)	Increase / (Decrease) %
Depreciation of property, plant and equipment	8	-	N.M	16	-	N.M

N.M. = not meaningful

# 1(b)(i) A statement of financial position (for the issuer and group), together with a comparative statement as at the end of the immediately preceding financial year.

	Group		Company	
	30.6.2014 \$'000 (Unaudited)	31.12.2013 \$'000 (Audited)	30.6.2014 \$'000 (Unaudited)	31.12.2013 \$'000 (Audited)
ASSETS	(	(,	<b>(,</b>	(,
Non-current assets				
Plant and equipment	41	53	-	-
Investment in subsidiaries		-	2,313	2,312
	41	53	2,313	2,312
Command accepts				
Current assets Trade and other receivables	7.040	7 474	50	540
Cash and cash equivalents	7,243 46,442	7,474 24,893	52 21,881	519 1
Amount due from subsidiary	40,442	24,093	21,001	'
, and an add not be desired.	53,685	32,367	21,937	520
Total assets	53,726	32,420	24,250	2,832
		<u> </u>		
EQUITY AND LIABILITIES				
Current liabilities				
Trade payables	-	-	-	-
Other payables	1,208	8,028	-	-
Accrued operating expense	1,023	4,478	23	2,026
Amount due to a subsidiary	-	-	-	1,293
Amount owing to related parties	2	21	-	-
Income tax payable	7,426	7,091		
	9,659	19,618	23	3,319
Net current assets / (liabilities)	44,026	12,749	21,914	(2,799)
Net assets / (liabilities)	44,067	12,802	24,227	(487)
Equity attributable to owners of the Company				
	00.0==	0.046	00.0==	0.015
Share capital	22,273	2,313	22,273	2,313
Merger reserve	(2,311)	(2,311)	-	- (0.000)
Retained earnings	24,105	12,800	1,954	(2,800)
Total equity	44,067	12,802	24,227	(487)
Total equity and liabilities	53,726	32,420	24,250	2,832
		•	,	*

- 1(b)(ii) In relation to the aggregate amount of group's borrowings and debt securities, specify the following as at the end of current financial period reported on with comparative figures as at the end of the immediately preceding financial year:
  - (A) the amount repayable in one year or less, or on demand: None
  - (B) the amount repayable after one year: None
  - (C) whether the amounts are secured or unsecured; and None
  - (D) details of any collaterals.
    None

## 1(c) A statement of cash flows (for the group), together with a comparative statement for the corresponding period of the immediately preceding financial year.

Cash Flows from Operating Activities	Cook Flows from Operating Activities	Q2 2014 \$'000 (Unaudited)	Q2 2013 \$'000 (Unaudited)	YTD 2014 \$'000 (Unaudited)	YTD 2013 \$'000 (Unaudited)
Adjustments for:   Depreciation of property, plant and equipment   8		44.700			40.000
Depreciation of property, plant and equipment		11,708	9,887	22,677	18,926
Operating cash flows before working capital changes         11,716         9,887         22,693         18,926           Changes in working capital         Decrease/(increase) in trade and other receivables         (556)         (1,482)         231         (2,174)           Increase/(decrease) in trade and other payables         103         583         (6,838)         (177)           Increase/(decrease) in accrued operating expenses         261         711         (3,457)         2,542           Net changes in working capital         (192)         (188)         (10,064)         191           Cash flows from operations         11,524         9,699         12,629         19,117           Income tax paid         (3,544)         (3,512)         (3,545)         (3,512)           Net cash flows from operating activities         7,980         6,187         9,084         15,605           Cash Flows from Investing Activities         2         (2)         (4)         (2)           Purchase of plant and equipment         -         (2)         (4)         (2)           Net cash used in investing Activities         -         (2)         (4)         (2)           Cash Flows from Financing Activities         -         (7,491)         -         (7,491)         -	•	0		40	
Changes in working capital Decrease/(increase) in trade and other receivables Increase/(decrease) in trade and other payables Increase/(decrease) in accrued operating expenses 261 711 (3,457) 2,542         231 (2,174) (177) (3,457) 2,542           Net changes in working capital (192) (188) (10,064) 191         (192) (188) (10,064) 191           Cash flows from operations Income tax paid (3,544) (3,512) (3,545) (3,512)         (3,544) (3,512) (3,545) (3,512)           Net cash flows from operating activities Purchase of plant and equipment - (2) (4) (2)           Net cash used in investing activities         - (2) (4) (2)           Cash Flows from Financing Activities         - (2) (4) (2)           Dividends paid to shareholders of a subsidiary proceeds from share issuance at IPO - (7,500) - (15,000)         - (7,500) - (15,000)           Proceeds from share issuance at IPO - (7,491) (7,500) - (10,69) - (10,69) - (10,69)         - (2,10,29) - (10,69) - (10,69)           Net cash (used in) / from financing activities         (7,491) (7,500) 12,469 (15,000)           Net increase / (decrease) in cash and cash equivalents and cash equivalents at beginning of the period 45,953 18,670 24,893 16,752			- 0.007	-	- 40.000
Decrease   (increase   in trade and other receivables   (556)   (1,482)   231   (2,174)     Increase   (decrease   in trade and other payables   103   583   (6,838)   (177)     Increase   (decrease   in accrued operating expenses   261   711   (3,457)   2,542     Net changes in working capital   (192)   (188)   (10,064)   191     Cash flows from operations   11,524   9,699   12,629   19,117     Income tax paid   (3,544)   (3,512)   (3,545)   (3,512)     Net cash flows from operating activities   7,980   6,187   9,084   15,605     Cash Flows from Investing Activities   2   (2)   (4)   (2)     Net cash used in investing activities   (7,491)   - (7,491)   - (7,491)   - (15,000)     Cash Flows from Financing Activities   (7,491)   - (7,500)   - (15,000)     Proceeds from share issuance at IPO   - (7,500)   - (15,000)     Proceeds from share issuance at IPO   - (7,491)   - (10,69)   -	Operating cash nows before working capital changes	11,716	9,887	22,693	18,926
Increase/(decrease) in trade and other payables   103   583   (6,838)   (1777     Increase/(decrease) in accrued operating expenses   261   711   (3,457)   2,542     Net changes in working capital   (192)   (188)   (10,064)   191     Cash flows from operations   11,524   9,699   12,629   19,117     Income tax paid   (3,544)   (3,512)   (3,545)   (3,512)     Net cash flows from operating activities   7,980   6,187   9,084   15,605     Cash Flows from Investing Activities   - (2)   (4)   (2)     Net cash used in investing activities   - (2)   (4)   (2)     Cash Flows from Financing Activities   - (2)   (4)   (2)     Cash Flows from Financing Activities   - (2)   (4)   (2)     Cash Flows from Financing Activities   - (7,491)   - (7,491)   - (7,491)   - (15,000)     Dividends paid to shareholders   (7,491)   - (7,500)   - (15,000)     Proceeds from share issuance at IPO   - (7,500)   - (15,000)     Proceeds from share issuance at IPO   - (7,500)   - (15,000)     Proceeds from financing activities   (7,491)   (7,500)   12,469   (15,000)     Net cash (used in) / from financing activities   489   (1,315)   21,549   603     Cash and cash equivalents at beginning of the period   45,953   18,670   24,893   16,752	Changes in working capital				
Increase/(decrease) in trade and other payables   103   583   (6,838)   (177)     Increase/(decrease) in accrued operating expenses   261   711   (3,457)   2,542     Net changes in working capital   (192)   (188)   (10,064)   191     Cash flows from operations   11,524   9,699   12,629   19,117     Income tax paid   (3,544)   (3,512)   (3,545)   (3,512)     Net cash flows from operating activities   7,980   6,187   9,084   15,605     Cash Flows from Investing Activities   - (2)   (4)   (2)     Net cash used in investing activities   - (2)   (4)   (2)     Cash Flows from Financing Activities   - (2)   (4)   (2)     Cash Flows from Financing Activities   - (7,491)   - (7,491)   - (15,000)     Dividends paid to shareholders   (7,491)   - (7,500)   - (15,000)     Proceeds from share issuance at IPO   - (7,500)   - (15,000)     Proceeds from share issuance at IPO   - (7,500)   - (15,000)     Proceeds from share issuance at IPO   - (7,500)   12,469   (15,000)     Net cash (used in) / from financing activities   (7,491)   (7,500)   12,469   (15,000)     Net increase / (decrease) in cash and cash equivalents   489   (1,315)   21,549   603     Cash and cash equivalents at beginning of the period   45,953   18,670   24,893   16,752	Decrease/(increase) in trade and other receivables	(556)	(1,482)	231	(2,174)
Net changes in working capital   (192) (188) (10,064)   191	Increase/(decrease) in trade and other payables	103	583	(6,838)	
Cash flows from operations         11,524         9,699         12,629         19,117           Income tax paid         (3,544)         (3,512)         (3,545)         (3,512)           Net cash flows from operating activities         7,980         6,187         9,084         15,605           Cash Flows from Investing Activities         Purchase of plant and equipment         -         (2)         (4)         (2)           Net cash used in investing activities         -         (2)         (4)         (2)           Cash Flows from Financing Activities         -         (2)         (4)         (2)           Cash Flows from Financing Activities         -         (2)         (4)         (2)           Cash Flows from Financing Activities         -         (7,491)         -         (7,491)         -           Dividends paid to shareholders         (7,491)         -         (7,491)         -         (15,000)           Proceeds from share issuance at IPO         -         -         -         21,029         -           IPO share issue expenses         -         -         -         (1,069)         -           Net cash (used in) / from financing activities         (7,491)         (7,500)         12,469         (15,000)	Increase/(decrease) in accrued operating expenses	261	711	(3,457)	2,542
Net cash flows from operating activities   7,980   6,187   9,084   15,605	Net changes in working capital	(192)	(188)	(10,064)	191
Net cash flows from operating activities   7,980   6,187   9,084   15,605			_	•	_
Net cash flows from operating activities         7,980         6,187         9,084         15,605           Cash Flows from Investing Activities         Purchase of plant and equipment         -         (2)         (4)         (2)           Net cash used in investing activities         -         (2)         (4)         (2)           Cash Flows from Financing Activities         -         (2)         (4)         (2)           Cash Flows from Financing Activities         (7,491)         -         (7,491)         -           Dividends paid to shareholders         (7,491)         -         (7,491)         -           Dividends paid to the then existing shareholders of a subsidiary         -         (7,500)         -         (15,000)           Proceeds from share issuance at IPO         -         -         21,029         -           IPO share issue expenses         -         -         -         (1,069)         -           Net cash (used in) / from financing activities         (7,491)         (7,500)         12,469         (15,000)           Net increase / (decrease) in cash and cash equivalents         489         (1,315)         21,549         603           Cash and cash equivalents at beginning of the period         45,953         18,670         24,893         16,752 <td>Cash flows from operations</td> <td>11,524</td> <td>9,699</td> <td>12,629</td> <td>19,117</td>	Cash flows from operations	11,524	9,699	12,629	19,117
Cash Flows from Investing Activities         Purchase of plant and equipment       -       (2)       (4)       (2)         Net cash used in investing activities       -       (2)       (4)       (2)         Cash Flows from Financing Activities         Dividends paid to shareholders       (7,491)       -       (7,491)       -         Dividends paid to the then existing shareholders of a subsidiary       -       (7,500)       -       (15,000)         Proceeds from share issuance at IPO       -       -       21,029       -         IPO share issue expenses       -       -       (1,069)       -         Net cash (used in) / from financing activities       (7,491)       (7,500)       12,469       (15,000)         Net increase / (decrease) in cash and cash equivalents       489       (1,315)       21,549       603         Cash and cash equivalents at beginning of the period       45,953       18,670       24,893       16,752	Income tax paid	(3,544)	(3,512)	(3,545)	(3,512)
Purchase of plant and equipment         -         (2)         (4)         (2)           Net cash used in investing activities         -         (2)         (4)         (2)           Cash Flows from Financing Activities         -         (2)         (4)         (2)           Dividends paid to shareholders         -         (7,491)         -         (7,491)         -           Dividends paid to the then existing shareholders of a subsidiary         -         (7,500)         -         (15,000)           Proceeds from share issuance at IPO         -         -         -         21,029         -           IPO share issue expenses         -         -         (1,069)         -           Net cash (used in) / from financing activities         (7,491)         (7,500)         12,469         (15,000)           Net increase / (decrease) in cash and cash equivalents         489         (1,315)         21,549         603           Cash and cash equivalents at beginning of the period         45,953         18,670         24,893         16,752	Net cash flows from operating activities	7,980	6,187	9,084	15,605
Purchase of plant and equipment         -         (2)         (4)         (2)           Net cash used in investing activities         -         (2)         (4)         (2)           Cash Flows from Financing Activities         -         (2)         (4)         (2)           Dividends paid to shareholders         -         (7,491)         -         (7,491)         -           Dividends paid to the then existing shareholders of a subsidiary         -         (7,500)         -         (15,000)           Proceeds from share issuance at IPO         -         -         -         21,029         -           IPO share issue expenses         -         -         (1,069)         -           Net cash (used in) / from financing activities         (7,491)         (7,500)         12,469         (15,000)           Net increase / (decrease) in cash and cash equivalents         489         (1,315)         21,549         603           Cash and cash equivalents at beginning of the period         45,953         18,670         24,893         16,752	Cash Flows from Investing Activities				
Net cash used in investing activities         -         (2)         (4)         (2)           Cash Flows from Financing Activities         Cash Flows from Financing Activities         Cash Flows from Financing Activities         (7,491)         -         (7,491)         -           Dividends paid to shareholders         (3,491)         -         (7,491)         -         (7,491)         -         (15,000)         -         (15,000)         -         (15,000)         -         -         (1,069)         -         -         -         (1,069)         -         -         -         (1,069)         -         -         Net cash (used in) / from financing activities         (7,491)         (7,500)         12,469         (15,000)         -         Net increase / (decrease) in cash and cash equivalents         489         (1,315)         21,549         603         -	<u> </u>		(2)	(4)	(2)
Cash Flows from Financing Activities         Dividends paid to shareholders       (7,491)       - (7,491)       -         Dividends paid to the then existing shareholders of a subsidiary       - (7,500)       - (15,000)         Proceeds from share issuance at IPO       (21,029)       -         IPO share issue expenses       (1,069)       -         Net cash (used in) / from financing activities       (7,491)       (7,500)       12,469       (15,000)         Net increase / (decrease) in cash and cash equivalents       489       (1,315)       21,549       603         Cash and cash equivalents at beginning of the period       45,953       18,670       24,893       16,752	·				
Dividends paid to shareholders       (7,491)       -       (7,491)       -         Dividends paid to the then existing shareholders of a subsidiary       -       (7,500)       -       (15,000)         Proceeds from share issuance at IPO       -       -       -       21,029       -         IPO share issue expenses       -       -       (1,069)       -         Net cash (used in) / from financing activities       (7,491)       (7,500)       12,469       (15,000)         Net increase / (decrease) in cash and cash equivalents       489       (1,315)       21,549       603         Cash and cash equivalents at beginning of the period       45,953       18,670       24,893       16,752	iver cash used in investing activities	<u>-</u>	(2)	(4)	(2)
Dividends paid to the then existing shareholders of a subsidiary - (7,500) - (15,000)  Proceeds from share issuance at IPO - 21,029 - IPO share issue expenses (1,069) - Net cash (used in) / from financing activities (7,491) (7,500) 12,469 (15,000)  Net increase / (decrease) in cash and cash equivalents	Cash Flows from Financing Activities				
subsidiary       -       (7,500)       -       (15,000)         Proceeds from share issuance at IPO       -       -       -       21,029       -         IPO share issue expenses       -       -       -       (1,069)       -         Net cash (used in) / from financing activities       (7,491)       (7,500)       12,469       (15,000)         Net increase / (decrease) in cash and cash equivalents       489       (1,315)       21,549       603         Cash and cash equivalents at beginning of the period       45,953       18,670       24,893       16,752		(7,491)	-	(7,491)	-
Proceeds from share issuance at IPO       -       -       21,029       -         IPO share issue expenses       -       -       -       (1,069)       -         Net cash (used in) / from financing activities       (7,491)       (7,500)       12,469       (15,000)         Net increase / (decrease) in cash and cash equivalents       489       (1,315)       21,549       603         Cash and cash equivalents at beginning of the period       45,953       18,670       24,893       16,752			4		
IPO share issue expenses       -       -       -       (1,069)       -         Net cash (used in) / from financing activities       (7,491)       (7,500)       12,469       (15,000)         Net increase / (decrease) in cash and cash equivalents       489       (1,315)       21,549       603         Cash and cash equivalents at beginning of the period       45,953       18,670       24,893       16,752	•	-	(7,500)	-	(15,000)
Net cash (used in) / from financing activities       (7,491)       (7,500)       12,469       (15,000)         Net increase / (decrease) in cash and cash equivalents       489       (1,315)       21,549       603         Cash and cash equivalents at beginning of the period       45,953       18,670       24,893       16,752		-	-	•	-
Net increase / (decrease) in cash and cash equivalents  489 (1,315) 21,549 603  Cash and cash equivalents at beginning of the period 45,953 18,670 24,893 16,752	·	(7.404)	(7.500)		- (45.000)
Cash and cash equivalents at beginning of the period 45,953 18,670 24,893 16,752	Net cash (used in) / from financing activities	(7,491)	(7,500)	12,469	(15,000)
Cash and cash equivalents at beginning of the period 45,953 18,670 24,893 16,752					
Cash and cash equivalents at beginning of the period 45,953 18,670 24,893 16,752	Net increase / (decrease) in cash and cash equivalents	489	(1,315)	21,549	603
Cash and cash equivalents at end of the period 46,442 17,355 46,442 17,355	Cash and cash equivalents at beginning of the period	45,953			16,752
	Cash and cash equivalents at end of the period	46,442	17,355	46,442	17,355

1(d)(i) A statement (for the issuer and group) showing either (i) all changes in equity or (ii) changes in equity other than those arising from capitalisation issues and distributions to shareholders, together with a comparative statement for the corresponding period of the immediately preceding financial year.

The Group (Unaudited)	Share capital \$'000	Merger reserves \$'000	Retained earnings \$'000	Total Equity \$'000
Balance at 1 Jan 2014	2,313	(2,311)	12,800	12,802
Proceeds from share issuance at IPO	21,029	-	-	21,029
IPO share issue expenses	(1,069)	-	-	(1,069)
Total comprehensive income for the period	-	-	9,167	9,167
Balance at 31 Mar 2014	22,273	(2,311)	21,967	41,929
Total comprehensive income for the period	-	-	9,629	9,629
Dividends paid to shareholders	-	-	(7,491)	(7,491)
Balance at 30 June 2014	22,273	(2,311)	24,105	44,067
Balance at 1 January 2013	1	-	12,095	12,096
Total comprehensive income for the period	_	_	7,356	7,356
Dividends paid to the then existing shareholders of a subsidiary	-	-	(7,500)	(7,500)
Balance at 31 March 2013	1	-	11,951	11,952
Total comprehensive income for the period			8,367	8,367
Dividends paid to the then existing shareholders of a subsidiary			(7,500)	(7,500)
Balance at 30 June 2013	1	-	12,818	12,819
The Company <sup>1</sup> (Unaudited)	Share capital	Merger reserves	Retained earnings	Total Equity
	\$'000	\$'000	\$'000	\$'000
Balance as at 1 January 2014	2,313	-	(2,800)	(487)
Proceeds from share issuance at IPO	21,029	-	-	21,029
IPO share issue expenses	(1,069)	-	-	(1,069)
Total comprehensive income for the period	-	-	12,457	12,457
Balance at 31 March 2014	22,273	-	9,657	31,930
Total comprehensive income for the period	-	-	(212)	(212)
Dividends paid to shareholders	-	-	(7,491)	(7,491)
Balance at 30 June 2014	22,273	-	1,954	24,227

<sup>&</sup>lt;sup>1</sup> There is no comparative statement of changes in equity for the Company for the prior year period as the Company was incorporated on 10 September 2013.

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State also the number of shares that may be issued on conversion of all the outstanding convertibles, as well as the number of shares held as treasury shares, if any, against the total number of issued shares excluding treasury shares of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

	Number of ordinary shares	Issued and paid- up share capital	
		\$	
Ordinary shares as at 1 January 2014 Issuance of shares on 30 January 2014, net of share	552,000,000	2,313,356	
issue expenses	105,143,000	19,959,628	
Ordinary shares as at 30 June 2014	657,143,000	22,272,984	

1(d)(iii)To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

#### **Number of ordinary shares**

	30.06.2014	31.12.2013
Total number of issued shares excluding treasury shares	657,143,000	552,000,000

1(d)(iv) A statement showing all sales, transfers, disposal, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

There are no shares held as treasury shares as at 30 June 2014.

2. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.

The results for Q2 2014 and YTD 2014 have not been audited nor reviewed by our auditors.

3. Where the figures have been audited or reviewed, the auditors' report (including any qualifications or emphasis of a matter).

Not applicable.

4. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statements have been applied.

Accounting policies and methods of computation used in the consolidated financial statements for the quarter are consistent with those applied in the financial statements for the year ended 31 December 2013.

5. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.

Not applicable

6. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

The Group	Q2 2014	Q2 2013	YTD 2014	YTD 2013
Profit attributable to owners of the company (\$'000)	9,629	8,367	18,796	15,723
Weighted average number of ordinary shares used in the computation of basic and diluted earnings per share	639,715,983	5,520	639,715,983	5,520
Basic and fully diluted earnings per share	1.51 cents	\$1,516	2.94 cents	\$2,848
Basic and fully diluted earnings per share adjusted for Restructuring Exercise and sub-division of shares pursuant to IPO <sup>1</sup>	1.51 cents	1.52 cents	2.94 cents	2.85 cents

#### Note:

- 7. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the:-
  - (a) current financial period reported on; and
  - (b) Immediately preceding financial year.

	Gro	oup	Company		
	30.6.2014 (Unaudited)	31.12.2013 (Audited)	30.6.2014 (Unaudited)	31.12.2013 (Audited)	
Net assets value (\$'000)	44,067	12,802	24,227	(487)	
Net assets per ordinary share at end of financial period <sup>1</sup> (cents)	6.71	2.32	3.69	(0.09)	

#### Note:

<sup>&</sup>lt;sup>1</sup> Earnings per share for Q2 2013 was computed after taking into account the 5,520 subscriber shares issued at incorporation and 551,994,480 shares issued in the Restructuring Exercise and subsequent sub-division of shares pursuant to the Company's IPO.

<sup>&</sup>lt;sup>1</sup> The calculation of net asset value per ordinary share was based on 657,143,000 shares as at 30 June 2014. (31 December 2013 : 552,000,000)

- 8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:-
  - (a) any significant factors that affected the turnover, costs and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and
  - (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

#### **Performance Review**

#### Revenue

Revenue grew by \$1.47 million or 10.3% from \$14.32 million in Q2 2013 to \$15.79 million in Q2 2014. This was due to increase in patient visits and increase in revenue from patients requiring higher intensity care.

#### Items of expense

#### Employee benefits

Employee benefits comprised remuneration paid to doctors, nurses as well as other medical and administrative support staff. These include salaries and wages, allowances, CPF contributions and staff benefits. Employee benefits increased by \$0.72 million or 27.7% from \$2.58 million in Q2 2013 to \$3.30 million in Q2 2014. The increase was mainly due to additional staff recruited to support growing business activities.

#### Operating lease expenses

Operating lease expenses increased by \$0.11 million or 156.3% from \$0.07 million in Q2 2013 to \$0.18 million in Q2 2014 as a result of 3 new operating leases that were effected in Q4 2013.

#### Other operating expenses

Other operating expenses comprised mainly audit fees, professional and legal fees, directors' fees, travelling and insurance expenses. Other operating expenses decreased by \$1.18 million or 66.2% from \$1.78 million in Q2 2013 to \$0.60 million in Q2 2014. This decrease was mainly due to professional fees accrued for in Q2 2013 in respect of restructuring of the Company in preparation for our listing.

#### **Income Tax**

Income tax expense increased by \$0.56 million or 36.8% from \$1.52 million in Q2 2013 to \$2.08 million in Q2 2014 due to higher profits in Q2 2014.

#### Profit after tax

The Group recorded a profit after tax of \$9.63 million in Q2 2014 compared to \$8.37 million in Q2 2013. The increase of \$1.26 million or 15.1% was mainly due to higher revenue generated in Q2 2014 compared to Q2 2013.

#### Review of the Group's financial

#### **Current assets**

Current assets comprised mainly trade and other receivables and cash and cash equivalents. Current assets increased by \$21.32 million. The increase was mainly due to the increase in cash and cash equivalents from the IPO proceeds received.

#### **Current liabilities**

Current liabilities comprised mainly other payables, accrued operating expenses and income tax payable. Current liabilities decreased by \$9.96 million. Other payables and accrued operating expenses decreased by \$10.28 million due to payment of professional fees incurred in connection with the Company's IPO exercise. Income tax payable increased by \$0.34 million due to increase in tax payable for Q2 2014 offset by payment of FY2013 taxes.

#### Equity attributable to owners of the Company

The increase was mainly attributable to profits earned during the period and increase in the share capital pursuant to the company's IPO exercise.

#### Review of the Group's cash flow

#### Cash flows from operating activities

In Q2 2014, net cash flows from operating activities amounted to \$7.98 million. This comprised operating cash flows before working capital changes of \$11.72 million less increase in working capital of \$0.19 million and income tax paid of \$3.55 million. The increase in working capital of \$0.19 million is mainly due to increases in trade and other receivables of \$0.55 million offset by increases in trade and other payables and accrued operating expenses of \$0.10 million and \$0.26 million respectively.

#### Cash flows from financing activities

Net cash used in financing activities was \$7.49 million for the payment of dividends to shareholders.

#### Net increase in cash and cash equivalent

The above resulted in net increase in cash and cash equivalents of \$0.49 million. Cash and cash equivalents totalled \$46.44 million as at 30 June 2014.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable

10. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

Our business is sustained to a large extent by the good economic performance of Singapore and countries in South East Asia. Continued economic stability of the region will enable the Group to maintain its level of profitability.

- 11. If a decision regarding dividend has been made, the required information has been disclosed.
  - (a) Whether an interim (final) ordinary dividend has been declared or recommended

Interim cash dividend of \$14 million has been declared.

(b) (i) Amount per share

\$ 0.0213 per share

#### (ii) Previous corresponding period

Nil. The Company was incorporated on 10 September 2013.

(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated)

The dividend is one tier tax exempt.

(d) The date the dividend is payable

To be announced at a later date.

(e) The date on which Registrable Transfers received by the Company (up to 5.00 pm) will be registered before entitlements to the dividend are determined.

To be announced at a later date.

12. If no dividend has been declared (recommended), a statement to that effect.

Not applicable.

13. If the Group has obtained a general mandate from the shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group does not have a general mandate from its shareholders for Interested Person Transactions pursuant to Rule 920(1)(a)(ii).

#### 14. Use of IPO proceeds

Pursuant to the IPO on 30 January 2014, the Company received net proceeds from the placement of new shares of \$17.3 million. The IPO proceeds have not been utilised as at the date of this announcement.

Use of proceeds from the IPO	Amount allocated \$'000	Amount Utilised \$'000	Amount Unutilised \$'000
Expanding repertoire of talent pool/healthcare services	10,381	-	10,381
Overseas expansion/improving quality of medical services	6,920	-	6,920
Total	17,301	-	17,301

#### 15. Confirmation pursuant to Rule 705(5)

The Board of Directors hereby confirms that to the best of the knowledge, nothing has come to their attention which may render the unaudited interim financial statements of the Group and the Company for the period ended 30 June 2014 to be false or misleading in any material aspect.

#### BY ORDER OF THE BOARD

Ang Peng Tiam Chief Executive Officer 7 August 2014

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, Hong Leong Finance Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST"). The Sponsor has not independently verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Joan Ling, Senior Vice President, Head of Corporate Finance. Telephone number: (65) 6415 9885 Email: joanling@hlf.com.sg